These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25151213)

  • 1. Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria.
    Klastersky J; Georgala A
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):268-78. PubMed ID: 25151213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging issues in the management of infections caused by multi-drug-resistant, gram-negative bacilli.
    Rice LB
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-37-47. PubMed ID: 23577496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic therapy for gram-negative bacteremia.
    Calandra T; Cometta A
    Infect Dis Clin North Am; 1991 Dec; 5(4):817-34. PubMed ID: 1783770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic resistance in cancer patients.
    Gudiol C; Carratalà J
    Expert Rev Anti Infect Ther; 2014 Aug; 12(8):1003-16. PubMed ID: 24834465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria.
    Falagas ME; Bliziotis IA; Kasiakou SK; Samonis G; Athanassopoulou P; Michalopoulos A
    BMC Infect Dis; 2005 Apr; 5():24. PubMed ID: 15819983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy for carbapenem-resistant Gram-negative bacteria.
    Zavascki AP; Bulitta JB; Landersdorfer CB
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1333-53. PubMed ID: 24191943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.
    Boyd N; Nailor MD
    Pharmacotherapy; 2011 Nov; 31(11):1073-84. PubMed ID: 22026395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant Gram-negative infections: the use of colistin.
    Michalopoulos AS; Karatza DC
    Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
    Walsh TR
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New aminoglycoside antibiotics.
    Dozzo P; Moser HE
    Expert Opin Ther Pat; 2010 Oct; 20(10):1321-41. PubMed ID: 20670208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxin antibiotics for gram-negative infections.
    Arnold TM; Forrest GN; Messmer KJ
    Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations in the choice and administration of agents for empiric antimicrobial therapy.
    Baughman RP
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-71-82. PubMed ID: 23577498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
    Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
    J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will new antimicrobials overcome resistance among Gram-negatives?
    Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The vicissitude of pathogenic bacteria isolated from critically ill patients in an intensive care unit during a period of using antibiotics].
    Wei HJ; Liu LL; Xiaoli LY; Wang YP; Huang D; Pian HY; Zhu YC
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Jan; 21(1):36-9. PubMed ID: 19141190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients.
    Cohen J
    J Antimicrob Chemother; 2013 Mar; 68(3):490-1. PubMed ID: 23152481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for monotherapy with beta-lactam antibiotics in the initial empirical management of febrile neutropenic cancer patients?
    Hathorn JW; Pizzo PA
    J Antimicrob Chemother; 1986 Mar; 17 Suppl A():41-54. PubMed ID: 3519563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistant gram-negative infections.
    Fraimow H; Nahra R
    Crit Care Clin; 2013 Oct; 29(4):895-921. PubMed ID: 24094384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.